# Recombinant Human Alkaline Phosphatase in Healthy Japanese Subjects

> **NCT04923282** · PHASE1 · COMPLETED · sponsor: **AM-Pharma** · enrollment: 34 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** single 1-hour IV infusion of 0.8 mg/kg recAP
- **BIOLOGICAL:** single 1-hour IV infusion of 1.6 mg/kg recAP
- **BIOLOGICAL:** single 1-hour IV infusion of 3.2 mg/kg recAP
- **BIOLOGICAL:** 1-hour infusions of 1.6 mg/kg recAP on Days 1, 2 and 3
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04923282
- **Lead sponsor:** AM-Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-07
- **Primary completion:** 2021-07-08
- **Final completion:** 2021-12-31
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2022-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04923282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04923282, "Recombinant Human Alkaline Phosphatase in Healthy Japanese Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04923282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*